Sphere Fluidics receives the prestigious IChemE Global Awards 2019 Biotechnology Award
We are honored to have been awarded the IChemE Global Awards 2019 Biotechnology award for our collaborative project with Lonza Biologics, UCB Celltech, Horizon Discovery, Alcyomics Ltd and CPI on “Defining and Developing New Generation Medicines”.
The award was announced at the IChemE Global Awards Dinner, 7th November 2019. The IChemE Global Awards celebrate chemical, process and biochemical engineering excellence and are widely recognised as the world’s most prestigious chemical engineering awards.
“We are proud to be a recipient of the IChemE Global Awards 2019 Biotechnology award,” said Frank F. Craig, PhD MBA, CEO of Sphere Fluidics. “We have made great progress in our efforts to advance the field of monoclonal antibody production using the robust microfluidic capabilities that the Cyto-Mine® single cell analysis system provides. We are delighted at the outcomes of the project and honored to be working with our partners to optimise the discovery and development of cost-effective next generation biotherapeutics.”
Sphere Fluidics retains ISO9001:2015 accreditation for the Life Sciences industry
At Sphere Fluidics, we focus on continuous improvement to remain at the forefront of single cell analysis. Our award winning, proprietary microfluidic technology allows the high- throughput analysis of isolated single cells which is helping to dramatically improve throughput in cell line development and biologics discovery. Compliance with global standards and regulations is at the very heart of what we do, as we strive to meet the needs of our customers.
We are therefore pleased to announce that we have retained our ISO9001:2015 accreditation for the development, manufacture and distribution of our products and services to the Life Sciences industry.
ISO 9001:2015 is an internationally recognised quality management certification that demonstrates our ability to consistently provide products and services that meet and, in many cases, exceed the required standards.
Director of Operations, Rob Treanor said “The team at Sphere Fluidics is committed to achieving the highest quality standards. As well as the continuous improvement methodology laid out in ISO9001:2015, we have also recently introduced a Kaizen framework to further develop our capabilities as we grow. Having quality at the heart of our culture ensures that we can continue to offer consistent product quality as the organisation scales”.
Sphere Fluidics and Peak Analysis and Automation introduce integrated micro-plate handling and single cell analysis capabilities
Integration of PAA’s S-LAB with Sphere Fluidics’ Cyto-Mine Single Cell Analysis System increases throughput in antibody discovery and cell line development
Launch at ELRIG Drug Discovery 2019, 5–6 November, Liverpool
Cambridge and Farnborough, UK, 5 November 2019: Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, and Peak Analysis and Automation (PAA), a leading supplier of intelligent laboratory automation solutions, today announced the optimization of the Cyto-Mine® Single Cell Analysis System through integration with PAA’s automated plate handler, S-LAB™. The addition of S-LAB to the Cyto-Mine provides researchers with a further streamlined solution for single cell analysis in biopharmaceutical workflows.
Combining automated micro-plate handling with the Cyto-Mine offers a simple solution to minimize hands-on involvement and reduce timelines in antibody discovery and cell line development. By replacing manual barcode scanning of multi-well microtiter plates and plate loading in the final picodroplet dispensing phase of the Cyto-Mine, the integration of S-LAB increases user flexibility, overall throughput and efficiency. The integrated system combines single cell screening, sorting, imaging, isolation and clone verification, and can process up to 40 million heterogenous mammalian cells in a few hours. It has a small footprint to enable use in a cell culture hood, which, coupled with the de-lidding capability of S-LAB, ensures that the processed cells remain sterile.
The launch follows the announcement of Sphere Fluidics and PAA’s collaboration in January 2019, and consolidates 10 months of research optimizing the communication between both devices. PAA has utilized the flexible application programming interface (API) of the Cyto-Mine Studio Software Suite to communicate easily with S-LAB across a range of analytical cellular procedures, offering a simple add-on for Cyto-Mine users.
Dr Rob Marchmont, VP of Sales and Marketing, Sphere Fluidics, commented: “Peak Analysis and Automation has a strong reputation as a trusted supplier of lab automation solutions, hence our decision to partner with the team to support our customers’ requirements for a complete, automated workflow. The integration of our Cyto-Mine with PAA’s S-LAB gives customers the freedom and flexibility to incorporate both instruments into multiple workflows, to further reduce their biopharmaceutical timelines. We will continue to work with PAA to further the opportunities in the synergy of our technologies.”
Dr Malcolm Crook, Technical Director, Peak Analysis and Automation, said: “This collaboration illustrates S-LAB’s cost-effectiveness and ease of use, in addition to its adaptability to different scientific applications. We look forward to our continued partnership with Sphere Fluidics to bring automated solutions to customers across a broad range of processes.”
The Cyto-Mine and S-LAB will be on display at Sphere Fluidics’ booth (D8) at ELRIG Drug Discovery from 5–6 November in Liverpool (PAA at Booth F3). Dr Zoe Nilsson, Sphere Fluidics’ Global Product Marketing Manager, will also be presenting ‘A Revolutionary Platform for Single Cell Analysis in Drug Discovery’ on 6 November at 12:45pm in the ‘Biomarker Strategies in Drug Discovery’ track.
Sphere Fluidics Dr Zoe Nilsson, Global Product Marketing Manager Tel: +44 (0)1223 804210 Email: firstname.lastname@example.org
About Sphere Fluidics
Sphere Fluidics develops and manufactures single cell analysis and monoclonality assurance systems for biologics discovery and cell line development. Sphere Fluidics’ Cyto-Mine® System integrates selective screening of tens of millions of single cells, sorting, dispensing, imaging and clone verification into a single automated platform to streamline workflows, reduce costs, improve throughput and enable high-value clones to be captured in a single run. Cyto-Mine® is underpinned by the Company’s patented, microfluidic picodroplet technology. Sphere Fluidics is located in Granta Park, Cambridgeshire (UK) and Monmouth Junction, New Jersey (USA). The Company has also internationalized its business via a global network of distributors. Follow Sphere Fluidics on Twitter @SphereFluidics and LinkedIn @Sphere Fluidics Limited.
About Peak Analysis and Automation
Peak Analysis & Automation (PAA) is a leading supplier of intelligent laboratory automation solutions, trusted by scientists across the globe within the pharmaceutical and biotechnology industries. The company designs and builds an extensive range of laboratory workcells and robots, storage products and automation accessories as well as providing its own unique software solutions. PAA is located in Farnborough, Hampshire (UK) and Colorado Springs, Colorado (USA) E: email@example.com W: www.paa-automation.com Twitter: @paautomation